ANI Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ANIP and other ETFs, options, and stocks.

About ANIP

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. 

CEO
Nikhil Lalwani
CEONikhil Lalwani
Employees
897
Employees897
Headquarters
Baudette, Minnesota
HeadquartersBaudette, Minnesota
Founded
1996
Founded1996
Employees
897
Employees897

ANIP Key Statistics

Market cap
1.96B
Market cap1.96B
Price-Earnings ratio
-117.64
Price-Earnings ratio-117.64
Dividend yield
Dividend yield
Average volume
513.17K
Average volume513.17K
High today
$95.22
High today$95.22
Low today
$79.39
Low today$79.39
Open price
$83.21
Open price$83.21
Volume
710.59K
Volume710.59K
52 Week high
$99.50
52 Week high$99.50
52 Week low
$52.50
52 Week low$52.50

Stock Snapshot

As of today, ANI Pharmaceuticals(ANIP) shares are valued at $91.35. The company's market cap stands at 1.96B, with a P/E ratio of -117.64.

As of 2025-11-08, ANI Pharmaceuticals(ANIP) stock has fluctuated between $79.39 and $95.22. The current price stands at $91.35, placing the stock +15.1% above today's low and -4.1% off the high.

The ANI Pharmaceuticals(ANIP)'s current trading volume is 710.59K, compared to an average daily volume of 513.17K.

In the last year, ANI Pharmaceuticals(ANIP) shares hit a 52-week high of $99.50 and a 52-week low of $52.50.

In the last year, ANI Pharmaceuticals(ANIP) shares hit a 52-week high of $99.50 and a 52-week low of $52.50.

ANIP News

TipRanks 3h
ANI Pharmaceuticals’ Earnings Call Highlights Record Growth

Ani Pharmaceuticals ((ANIP)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI...

TipRanks 23h
ANI Pharmaceuticals Reports Record Q3 2025 Results

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its investors. Meet Your E...

TipRanks 1d
ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals, retaining the price target of $121.00. Meet Your ETF AI Analyst Discov...

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More ANIP News

Nasdaq 2d
ANI Pharmaceuticals Posts Q3 Net Profit As Rare Disease Brands Revenue Surges; Lifts Annual Outlook

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Friday registered a net profit for the third quarter, supported by increased revenue from rare disease and brand...

ANI Pharmaceuticals Posts Q3 Net Profit As Rare Disease Brands Revenue Surges; Lifts Annual Outlook
Simply Wall St 7d
Is ANI Pharmaceuticals Still Undervalued After Its Recent Surge?

ANI Pharmaceuticals (ANIP) has caught some interest lately, with its stock moving even though there is no major news event scheduled. Investors are taking a clo...

Is ANI Pharmaceuticals Still Undervalued After Its Recent Surge?

People also own

Based on the portfolios of people who own ANIP. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.